ZURICH Nov 21 Novartis said on Monday
it was buying U.S.-based Selexys Pharmaceuticals in a deal worth
up to $665 million, as the Swiss drugmaker expands its pipeline
of medicines to combat blood diseases.
Novartis exercised its right to acquire Selexys after a
phase II trial evaluating the Oklahoma City-based company's
investigational medicine SelG1, aimed at reducing vaso-occlusive
pain crises in patients with sickle cell disease.
Such crises occur in adolescent and adult patients where
sickled red blood cells obstruct circulation in blood vessels.
(Reporting by John Miller)